Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES SHARES FOR DEBT SETTLEMENT AND AWARDS OPTION GRANTS

Ventripoint Diagnostics Ltd. has received approval from the TSX Venture Exchange and has issued 4,276,964 common shares of the corporation to settle an aggregate of $427,696.35 of debt owed to certain arm's-length creditors of the corporation at a price of 10 cents per share.

The shares are subject to a hold period of four months and one day. The corporation determined to satisfy the indebtedness with shares to preserve its cash for development of its business.

The company also issued option grants on Jan. 20, 2026. The corporation granted an aggregate of 2,516,500 options to directors, officers, employees, contractors and consultants of the corporation with an exercise price of 12 cents and terms of between two and 10 years, vesting from immediately to over a three-year period. Of these option grants, 200,000 were awarded to directors, and an additional 1.3 million were awarded to officers, some of which are also directors of the corporation.

These annual option grants are an important part of incentivizing stakeholders to drive value in the corporation.

Since the last update (see the news release dated June 17, 2025), a total of 780,000 options were exercised with a weighted-average price of approximately 10.5 cents per share for gross proceeds to the corporation of $81,800. There are currently 16,683,500 option grants outstanding with exercise prices between 10 cents and 50 cents with a weighted-average price of 17 cents, and 14,555,167 of these option grants have vested.

The corporation has approximately 2.0 million options available for future grants under the stock option plan as approved by shareholders at the past special and annual general meeting of the corporation.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.